Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225384 | 0.83 | MEN1 (0.36) | HRH4PDPK1ALDH1A1HPGDAPEX1 | |
| SCHEMBL4220787 | 0.83 | MEN1 (0.36) | HRH4PDPK1ALDH1A1HPGDAPEX1 | |
| SCHEMBL4787473 | 0.76 | HRH4 (0.54) | HRH4MAP2K1KDM4EPDPK1ALDH1A1 | |
| SCHEMBL4229415 | 0.73 | ALDH1A1 (0.35) | KDM4EALDH1A1LMNA | |
| SCHEMBL16571364 | 0.73 | MAP2K1 (0.50) | HRH4MAP2K1KDM4EPDPK1ALDH1A1 | |
| SCHEMBL29063260 | 0.73 | HRH4 (0.40) | HRH4MAP2K1KDM4EPDPK1ALDH1A1 | |
| SCHEMBL16571303 | 0.69 | GRM2 (0.42) | KDM4EPDPK1ALDH1A1LMNAHPGD | |
| SCHEMBL25532019 | 0.66 | EIF4A3 (0.37) | HRH4MAP2K1ALDH1A1LMNA | |
| SCHEMBL16571384 | 0.66 | GPER1 (0.38) | KDM4EPDPK1ALDH1A1LMNAHPGD | |
| SCHEMBL3725570 | 0.65 | CES2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2009-11-26 | — | — | US | disclosed |
| US-7598397-B2 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | DECODE GENETICS EHF (IS) | 2009-10-06 | — | — | US | disclosed |
| EP-1812388-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044000-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | SAGA INVESTMENTS LLC | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGS2 | HRH4 1199/4885MAP2K1 3492/4885KDM4E 3447/4885 |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | PTGIS, PTGIR, PTGS2 | HRH4 1199/4885MAP2K1 3492/4885KDM4E 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.